## Christopher J Kane

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11191299/publications.pdf

Version: 2024-02-01

258 papers

12,340 citations

<sup>26567</sup> 56
h-index

100 g-index

260 all docs

260 docs citations

times ranked

260

11569 citing authors

#	Article	IF	CITATIONS
1	Prostate Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 19-30.	2.3	544
2	Renal cell cancer stage migration. Cancer, 2008, 113, 78-83.	2.0	535
3	Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature, 2015, 521, 94-98.	13.7	451
4	TIME TO STONE PASSAGE FOR OBSERVED URETERAL CALCULI: A GUIDE FOR PATIENT EDUCATION. Journal of Urology, 1999, 162, 688-691.	0.2	394
5	Impact of Obesity on Biochemical Control After Radical Prostatectomy for Clinically Localized Prostate Cancer: A Report by the Shared Equal Access Regional Cancer Hospital Database Study Group. Journal of Clinical Oncology, 2004, 22, 446-453.	0.8	366
6	Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer, 2008, 112, 2664-2670.	2.0	361
7	Prostate Cancer, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 686-718.	2.3	294
8	Obesity-Related Plasma Hemodilution and PSA Concentration Among Men With Prostate Cancer. JAMA - Journal of the American Medical Association, 2007, 298, 2275.	3.8	291
9	Association of Black Race With Prostate Cancer–Specific and Other-Cause Mortality. JAMA Oncology, 2019, 5, 975.	3.4	288
10	Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology, 2003, 61, 607-611.	0.5	235
11	Prostate Size and Risk of High-Grade, Advanced Prostate Cancer and Biochemical Progression After Radical Prostatectomy: A Search Database Study. Journal of Clinical Oncology, 2005, 23, 7546-7554.	0.8	213
12	Prospective comparison of unenhanced spiral computed tomography and intravenous urogram in the evaluation of acute flank pain. Urology, 1998, 52, 982-987.	0.5	210
13	Diffusion-Weighted Imaging in Cancer: Physical Foundations and Applications of Restriction Spectrum Imaging. Cancer Research, 2014, 74, 4638-4652.	0.4	179
14	Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 581-590.	0.8	162
15	Upgrading and Downgrading of Prostate Needle Biopsy Specimens: Risk Factors and Clinical Implications. Urology, 2007, 69, 495-499.	0.5	158
16	Obesity, Serum Prostate Specific Antigen and Prostate Size: Implications for Prostate Cancer Detection. Journal of Urology, 2006, 175, 500-504.	0.2	156
17	Tumor infiltrating B-cells are increased in prostate cancer tissue. Journal of Translational Medicine, 2014, 12, 30.	1.8	137
18	Impact of obesity on prostate cancer recurrence after radical prostatectomy: Data from CaPSURE. Urology, 2005, 66, 1060-1065.	0.5	135

#	Article	IF	CITATIONS
19	Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology, 2003, 61, 736-741.	0.5	133
20	Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer, 2006, 107, 2384-2391.	2.0	129
21	Prospective Comparison of Computerized Tomography and Excretory Urography in the Initial Evaluation of Asymptomatic Microhematuria. Journal of Urology, 2002, 168, 2457-2460.	0.2	126
22	Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology, 2001, 58, 723-728.	0.5	122
23	CURRENT MANAGEMENT OF SEVERELY ENCRUSTED URETERAL STENTS WITH A LARGE ASSOCIATED STONE BURDEN. Journal of Urology, 2000, 164, 648-650.	0.2	119
24	Statin medication use and the risk of biochemical recurrence after radical prostatectomy. Cancer, 2010, 116, 3389-3398.	2.0	112
25	Serum Lipid Profile and Risk of Prostate Cancer Recurrence: Results from the SEARCH Database. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2349-2356.	1.1	111
26	Multi-institutional Validation of the CAPRA-S Score to Predict Disease Recurrence and Mortality After Radical Prostatectomy. European Urology, 2014, 65, 1171-1177.	0.9	110
27	Multigene Methylation Analysis for Detection and Staging of Prostate Cancer. Clinical Cancer Research, 2005, 11, 6582-6588.	3.2	106
28	Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer, 2006, 107, 1265-1272.	2.0	102
29	Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology, 2002, 60, 670-674.	0.5	100
30	Percent of Prostate Needle Biopsy Cores With Cancer is Significant Independent Predictor of Prostate Specific Antigen Recurrence Following Radical Prostatectomy: Results From SEARCH Database. Journal of Urology, 2003, 169, 2136-2141.	0.2	95
31	Treatment Trends for Stage I Renal Cell Carcinoma. Journal of Urology, 2011, 186, 394-399.	0.2	95
32	Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system. Urology, 2000, 56, 1016-1020.	0.5	89
33	OBESITY AND BIOCHEMICAL OUTCOME FOLLOWING RADICAL PROSTATECTOMY FOR ORGAN CONFINED DISEASE WITH NEGATIVE SURGICAL MARGINS. Journal of Urology, 2004, 172, 520-524.	0.2	89
34	Ethnic group-related differences in CpG hypermethylation of theGSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer. International Journal of Cancer, 2005, 116, 174-181.	2.3	88
35	Feasibility and efficacy of neoadjuvant sunitinib before nephronâ€sparing surgery. BJU International, 2010, 106, 1270-1276.	1.3	86
36	CpG Hypermethylation of MDR1 Gene Contributes to the Pathogenesis and Progression of Human Prostate Cancer. Cancer Research, 2004, 64, 5956-5962.	0.4	85

#	Article	IF	Citations
37	Obesity is associated with castrationâ€resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. BJU International, 2012, 110, 492-498.	1.3	82
38	Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation. Journal of Clinical Oncology, 2019, 37, 2062-2071.	0.8	80
39	Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. European Urology, 2017, 72, 845-852.	0.9	79
40	Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH. Clinical Genitourinary Cancer, 2017, 15, 60-66.e2.	0.9	79
41	Delay of Radical Prostatectomy and Risk of Biochemical Progression in Men With Low Risk Prostate Cancer. Journal of Urology, 2006, 175, 1298-1303.	0.2	75
42	Outcomes After Radical Prostatectomy Among Men Who Are Candidates for Active Surveillance: Results From the SEARCH Database. Urology, 2010, 76, 695-700.	0.5	75
43	Delayed radical prostatectomy for intermediateâ€risk prostate cancer is associated with biochemical recurrence: Possible implications for active surveillance from the SEARCH database. Prostate, 2013, 73, 409-417.	1.2	75
44	DIFFERENCES IN COMPLICATIONS AND OUTCOMES FOR OBESE PATIENTS UNDERGOING LAPAROSCOPIC RADICAL, PARTIAL OR SIMPLE NEPHRECTOMY. Journal of Urology, 2004, 172, 2287-2291.	0.2	74
45	ABILITY OF 2 PRETREATMENT RISK ASSESSMENT METHODS TO PREDICT PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY: DATA FROM CaPSURE. Journal of Urology, 2005, 173, 1126-1131.	0.2	69
46	Outcomes and complications of pelvic lymph node dissection during robotic-assisted radical prostatectomy. World Journal of Urology, 2013, 31, 481-488.	1.2	69
47	Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castrationâ€resistant prostate cancer, and mortality after radical prostatectomy. Cancer, 2014, 120, 197-204.	2.0	69
48	Changing Nature of High Risk Patients Undergoing Radical Prostatectomy. Journal of Urology, 2007, 177, 113-117.	0.2	67
49	Obesity as a predictor of adverse outcome across black and white race. Cancer, 2009, 115, 5263-5271.	2.0	66
50	THE IMPACT OF OBESITY ON HEALTH RELATED QUALITY OF LIFE BEFORE AND AFTER RADICAL PROSTATECTOMY (DATA FROM CaPSURE). Journal of Urology, 2005, 173, 1132-1138.	0.2	62
51	Race, biochemical disease recurrence, and prostate–specific antigen doubling time after radical prostatectomy. Cancer, 2007, 110, 2202-2209.	2.0	62
52	A Receptor-targeted Fluorescent Radiopharmaceutical for Multireporter Sentinel Lymph Node Imaging. Radiology, 2012, 265, 186-193.	3.6	62
53	Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database. Urology, 2003, 61, 742-747.	0.5	61
54	Smoking influences aberrant CpG hypermethylation of multiple genes in human prostate carcinoma. Cancer, 2006, 106, 79-86.	2.0	61

#	Article	IF	CITATIONS
55	Laparoscopic partial nephrectomy with temporary arterial occlusion: description of technique and renal functional outcomes. Urology, 2004, 63, 241-246.	0.5	60
56	Small Transrectal Ultrasound Volume Predicts Clinically Significant Gleason Score Upgrading After Radical Prostatectomy: Results From the SEARCH Database. Journal of Urology, 2008, 179, 523-528.	0.2	60
57	Should a Positive Surgical Margin Following Radical Prostatectomy be Pathological Stage T2 or T3? Results From the SEARCH Database. Journal of Urology, 2003, 169, 2142-2146.	0.2	58
58	Do younger men have better biochemical outcomes after radical prostatectomy?. Urology, 2004, 63, 518-522.	0.5	58
59	Comparison of Preoperative Prostate Specific Antigen Density and Prostate Specific Antigen for Predicting Recurrence After Radical Prostatectomy: Results from the Search Data Base. Journal of Urology, 2003, 169, 969-973.	0.2	55
60	Predicting Unilateral Prostate Cancer Based on Biopsy Features: Implications for Focal Ablative Therapy—Results From the SEARCH Database. Journal of Urology, 2007, 178, 1249-1252.	0.2	55
61	Yield of imaging and scintigraphy assessing biochemical failure in prostate cancer patients. Urologic Oncology: Seminars and Original Investigations, 1997, 3, 108-112.	0.8	53
62	OBESITY AND PROSTATE CANCER CLINICAL RISK FACTORS AT PRESENTATION: DATA FROM CaPSURE. Journal of Urology, 2005, 173, 732-736.	0.2	53
63	Education predicts quality of life among men with prostate cancer cared for in the department of Veterans affairs. Cancer, 2007, 109, 1769-1776.	2.0	53
64	Adequacy of lymphadenectomy among men undergoing robotâ€essisted laparoscopic radical prostatectomy. BJU International, 2010, 105, 88-92.	1.3	53
65	Nerve-targeted probes for fluorescence-guided intraoperative imaging. Theranostics, 2018, 8, 4226-4237.	4.6	51
66	PGDB: a curated and integrated database of genes related to the prostate. Nucleic Acids Research, 2003, 31, 291-293.	6.5	50
67	Obesity and oncological outcome after radical prostatectomy: impact of prostateâ€specific antigenâ€based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center Databases. BJU International, 2008, 102, 969-974.	1.3	49
68	Effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equalâ€access health care setting. Cancer, 2012, 118, 4999-5007.	2.0	49
69	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. JAMA Oncology, 2020, 6, 1912.	3.4	49
70	PREOPERATIVE MODEL FOR PREDICTING PROSTATE SPECIFIC ANTIGEN RECURRENCE AFTER RADICAL PROSTATECTOMY USING PERCENT OF BIOPSY TISSUE WITH CANCER, BIOPSY GLEASON GRADE AND SERUM PROSTATE SPECIFIC ANTIGEN. Journal of Urology, 2004, 171, 2215-2220.	0.2	48
71	Natural History of Persistently Elevated Prostate Specific Antigen After Radical Prostatectomy: Results From the SEARCH Database. Journal of Urology, 2009, 182, 2250-2256.	0.2	47
72	Risk Stratification of Men with Gleason Score 7 to 10 Tumors by Primary and Secondary Gleason Score: Results from the SEARCH Database. Urology, 2007, 70, 277-282.	0.5	46

#	Article	IF	CITATIONS
73	Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the <scp>S</scp> hared <scp>E</scp> qual <scp>A</scp> ccess <scp>R</scp> egional <scp>C</scp> ancer <scp>H</scp> ospital ( <scp>SEARCH</scp> ) database. BJU International, 2014, 114, 661-666.	1.3	46
74	Thresholds for <scp>PSA</scp> doubling time in men with nonâ€metastatic castrationâ€resistant prostate cancer. BJU International, 2017, 120, E80-E86.	1.3	46
75	Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7,) Tj ETQq1 1 0.78431 Stratification: A Systematic Review. European Urology Focus, 2017, 3, 487-497.	14 rgBT /C 1.6	verlock 10 46
76	The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy. Cancer, 2003, 98, 2344-2350.	2.0	45
77	Obesity and positive surgical margins by anatomic location after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. BJU International, 2008, 102, 964-968.	1.3	44
78	Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial. Journal of Urology, 2018, 199, 53-59.	0.2	44
79	Association of Treatment With 5î±-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer. JAMA Internal Medicine, 2019, 179, 812.	2.6	44
80	Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. Journal of Urology, 2016, 196, 1408-1414.	0.2	43
81	Association Between African American Race and Clinical Outcomes in Men Treated for Low-Risk Prostate Cancer With Active Surveillance. JAMA - Journal of the American Medical Association, 2020, 324, 1747.	3.8	43
82	SECOND PRIMARY MALIGNANCIES IN T1-3N0 PROSTATE CANCER PATIENTS TREATED WITH RADIATION THERAPY WITH 10-YEAR FOLLOWUP. Journal of Urology, 1998, 159, 946-949.	0.2	42
83	Glycemic control and prostate cancer progression: Results from the SEARCH database. Prostate, 2010, 70, 1540-1546.	1,2	42
84	Diabetes and Outcomes After Radical Prostatectomy: Are Results Affected by Obesity and Race? Results from the Shared Equal-Access Regional Cancer Hospital Database. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 9-17.	1.1	42
85	Impact of patient educational level on treatment for patients with prostate cancer: data from CaPSURE. Urology, 2003, 62, 1035-1039.	0.5	40
86	Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. Cancer, 2004, 100, 1633-1638.	2.0	40
87	Impact of Family History on Prostate Cancer Mortality in White Men Undergoing Prostate Specific Antigen Based Screening. Journal of Urology, 2015, 193, 75-79.	0.2	40
88	Sociodemographic and Clinical Risk Characteristics of Patients With Prostate Cancer Within the Veterans Affairs Health Care System: Data From CaPSURE. Journal of Urology, 2003, 170, 905-908.	0.2	38
89	Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the SEARCH database. BJU International, 2009, 104, 1452-1456.	1.3	38
90	How to Minimize Lymphoceles and Treat Clinically Symptomatic Lymphoceles After Radical Prostatectomy. Current Urology Reports, 2014, 15, 445.	1.0	38

#	Article	IF	Citations
91	A natural history of weight change in men with prostate cancer on androgenâ€deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU International, 2011, 107, 924-928.	1.3	37
92	Does Timing of Cytoreductive Nephrectomy Impact Patient Survival With Metastatic Renal Cell Carcinoma in the Tyrosine Kinase Inhibitor Era? A Multi-institutional Study. Urology, 2013, 81, 805-812.	0.5	37
93	PSA in the New Millennium: A Powerful Predictor of Prostate Cancer Prognosis and Radical Prostatectomy Outcomes — Results from the SEARCH Database. European Urology, 2008, 53, 758-766.	0.9	34
94	A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. Journal of Translational Medicine, 2011, 9, 185.	1.8	34
95	Laparoscopic versus Open Cytoreductive Nephrectomy in Advanced Renal-Cell Carcinoma. Journal of Endourology, 2006, 20, 504-508.	1.1	33
96	Obesity, Prostate-Specific Antigen Nadir, and Biochemical Recurrence After Radical Prostatectomy: Biology or Technique? Results from the SEARCH Database. European Urology, 2012, 62, 910-916.	0.9	33
97	Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma. European Urology, 2021, 80, 20-31.	0.9	33
98	Risk Stratification for Biochemical Recurrence in Men With Positive Surgical Margins or Extracapsular Disease After Radical Prostatectomy: Results From the SEARCH Database. Journal of Urology, 2008, 179, 1791-1796.	0.2	32
99	Obesity, race, and longâ€ŧerm prostate cancer outcomes. Cancer, 2020, 126, 3733-3741.	2.0	32
100	THE ROLE OF IMAGING STUDIES AND MOLECULAR MARKERS FOR SELECTING CANDIDATES FOR RADICAL PROSTATECTOMY. Urologic Clinics of North America, 2001, 28, 459-472.	0.8	30
101	Body Mass Index, Prostate Weight and Transrectal Ultrasound Prostate Volume Accuracy. Journal of Urology, 2007, 178, 990-995.	0.2	30
102	Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database. Cancer, 2017, 123, 4199-4206.	2.0	30
103	Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes and Control, 2018, 29, 581-588.	0.8	30
104	Effect of Race on Biochemical Disease-free Outcome in Patients with Prostate Cancer Treated with Definitive Radiation Therapy in an Equal-Access Health Care System: Radiation Oncology Report of the Department of Defense Center for Prostate Disease Research. Radiology, 2002, 225, 420-426.	3.6	29
105	The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained: results from the Shared Equal Access Regional Cancer Hospital Database. BJU International, 2008, 102, 1074-1079.	1.3	29
106	Comparison of Rates and Risk Factors for Development of Osteoporosis and Fractures After Radical or Partial Nephrectomy. Urology, 2011, 78, 614-619.	0.5	29
107	Preoperative sentinel lymph node mapping of the prostate using PET/CT fusion imaging and Ga-68-labeled tilmanocept in an animal model. Clinical and Experimental Metastasis, 2012, 29, 673-680.	1.7	29
108	Prostate diffusion imaging with distortion correction. Magnetic Resonance Imaging, 2015, 33, 1178-1181.	1.0	29

#	Article	IF	Citations
109	Is Biopsy Gleason Score Independently Associated With Biochemical Progression Following Radical Prostatectomy After Adjusting for Pathological Gleason Score?. Journal of Urology, 2006, 176, 2453-2458.	0.2	28
110	Association of Cigarette Smoking With Interval to Biochemical Recurrence After Radical Prostatectomy: Results from the SEARCH Database. Urology, 2010, 76, 1218-1223.	0.5	28
111	Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system. International Journal of Radiation Oncology Biology Physics, 2003, 55, 964-969.	0.4	27
112	Effect of BMI on Primary Treatment of Prostate Cancer. Urology, 2008, 72, 406-411.	0.5	27
113	Optimization via specific fluorescence brightness of a receptor-targeted probe for optical imaging and positron emission tomography of sentinel lymph nodes. Journal of Biomedical Optics, 2013, 18, 101315.	1.4	26
114	Unenhanced helical computed tomography in the evaluation of acute flank pain. Current Opinion in Urology, 2000, 10, 123-129.	0.9	25
115	Racial Discrepancies in Overall Survival among Men Treated with <sup>223</sup> Radium. Journal of Urology, 2020, 203, 331-337.	0.2	25
116	Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels. Cancer, 2004, 101, 748-753.	2.0	24
117	Optimal Timing, Cutoff, and Method of Calculation of Preoperative Prostate-Specific Antigen Velocity to Predict Relapse After Prostatectomy: A Report from SEARCH. Urology, 2007, 69, 732-737.	0.5	24
118	Race and Time from Diagnosis to Radical Prostatectomy: Does Equal Access Mean Equal Timely Access to the Operating Room?—Results from the SEARCH Database. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1208-1212.	1.1	24
119	The impact of pathologic staging on the longâ€term oncologic outcomes of patients with clinically highâ€risk prostate cancer. Cancer, 2014, 120, 1656-1662.	2.0	24
120	Fluorescence-Based Molecular Imaging of Porcine Urinary Bladder Sentinel Lymph Nodes. Journal of Nuclear Medicine, 2017, 58, 547-553.	2.8	24
121	Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 252-260.	2.0	24
122	Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis. Clinical Genitourinary Cancer, 2019, 17, e505-e512.	0.9	24
123	Effects of Hospital Procedure Volume and Resident Training on Clinical Outcomes and Resource Use in Radical Retropubic Prostatectomy Surgery in the Department of Veterans Affairs. Journal of Urology, 2008, 179, 272-279.	0.2	23
124	Detectable Prostate-Specific Antigen Nadir During Androgen-Deprivation Therapy Predicts Adverse Prostate Cancer–Specific Outcomes: Results from the SEARCH Database. European Urology, 2014, 65, 620-627.	0.9	23
125	Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer. Journal of Translational Medicine, 2020, 18, 214.	1.8	23
126	Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials. Cancer, 2022, 128, 770-777.	2.0	23

#	Article	IF	CITATIONS
127	Improved Clinical Staging System Combining Biopsy Laterality and TNM Stage for Men With T1c and T2 Prostate Cancer: Results From the SEARCH Database. Journal of Urology, 2003, 169, 2129-2135.	0.2	22
128	Comparison of rates and risk factors for development of anaemia and erythropoiesisâ€stimulating agent utilization after radical or partial nephrectomy. BJU International, 2012, 109, 1019-1025.	1.3	22
129	Factors predicting skeletalâ€related events in patients with bone metastatic castrationâ€resistant prostate cancer. Cancer, 2017, 123, 1528-1535.	2.0	22
130	Number of Unfavorable Intermediateâ€Risk Factors Predicts Pathologic Upstaging and Prostate Cancerâ€Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database. Prostate, 2017, 77, 154-163.	1.2	22
131	Management of pelvic lymphoceles following robot-assisted laparoscopic radical prostatectomy. Urology Annals, 2012, 4, 111.	0.3	22
132	Prostate Biopsy Tumor Extent but Not Location Predicts Recurrence After Radical Prostatectomy: Results From CaPSURE. Journal of Urology, 2006, 175, 125-129.	0.2	21
133	Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone?. BJU International, 2009, 103, 603-608.	1.3	21
134	Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. BJU International, 2010, 105, 28-33.	1.3	21
135	Definition and preoperative predictors of persistently elevated prostateâ€specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU International, 2010, 105, 1541-1547.	1.3	20
136	Freedom From a Detectable Ultrasensitive Prostate-specific Antigen at Two Years After Radical Prostatectomy Predicts a Favorable Clinical Outcome: Analysis of the SEARCH Database. Urology, 2010, 75, 439-444.	0.5	20
137	MRI-Derived Restriction Spectrum Imaging Cellularity Index is Associated with High Grade Prostate Cancer on Radical Prostatectomy Specimens. Frontiers in Oncology, 2015, 5, 30.	1.3	20
138	Positive surgical margins in radical prostatectomy patients do not predict longâ€term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (⟨scp⟩SEARCH⟨/scp⟩) cohort. BJU International, 2016, 117, 244-248.	1.3	20
139	Restriction spectrum imaging improves MRI-based prostate cancer detection. Abdominal Radiology, 2016, 41, 946-953.	1.0	20
140	Poorly controlled diabetes increases the risk of metastases and castrationâ€resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database. Cancer, 2019, 125, 2861-2867.	2.0	20
141	A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand. Science Advances, 2021, 7, .	4.7	20
142	Health-related quality of life for men with prostate cancer and diabetes: A longitudinal analysis from CaPSURE. Urology, 2006, 68, 1242-1247.	0.5	19
143	Do Racial Differences in Prostate Size Explain Higher Serum Prostate-Specific Antigen Concentrations Among Black Men?. Urology, 2007, 69, 1138-1142.	0.5	19
144	What are the Factors Associated With Short Prostate Specific Antigen Doubling Time After Radical Prostatectomy? A Report From the SEARCH Database Group. Journal of Urology, 2008, 180, 1980-1985.	0.2	19

#	Article	IF	Citations
145	Voxel Level Radiologic–Pathologic Validation of Restriction Spectrum Imaging Cellularity Index with Gleason Grade in Prostate Cancer. Clinical Cancer Research, 2016, 22, 2668-2674.	3.2	19
146	Is a Positive Bladder Neck Margin Truly a T4 Lesion in the Prostate Specific Antigen Era? Results From the SEARCH Database. Journal of Urology, 2008, 179, 124-129.	0.2	18
147	Exposure to Agent Orange is a significant predictor of prostateâ€specific antigen (PSA)â€based recurrence and a rapid PSA doubling time after radical prostatectomy. BJU International, 2009, 103, 1168-1172.	1.3	18
148	Body Mass Index and Prostate Specific Antigen as Predictors of Adverse Pathology and Biochemical Recurrence After Prostatectomy. Journal of Urology, 2009, 182, 491-498.	0.2	18
149	Do Nomograms Designed to Predict Biochemical Recurrence (BCR) Do a Better Job of Predicting More Clinically Relevant Prostate Cancer Outcomes than BCR? A Report from the SEARCH Database Group. Urology, 2013, 82, 53-59.	0.5	18
150	Minimally Invasive Cystectomy Is Associated With Improved Perioperative Patient Safety Outcomes Compared With Open Cystectomy in a National Cohort. Urology, 2014, 84, 314-320.	0.5	18
151	Robotic-assisted Fluorescence Sentinel Lymph Node Mapping Using Multimodal Image Guidance in an Animal Model. Urology, 2014, 84, 982.e9-982.e14.	0.5	18
152	Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1188-1193.	0.4	18
153	Limitations of Prostate Specific Antigen Doubling Time Following Biochemical Recurrence After Radical Prostatectomy: Results From the SEARCH Database. Journal of Urology, 2008, 179, 1785-1790.	0.2	17
154	Does early prostateâ€specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group. BJU International, 2009, 104, 1604-1609.	1.3	17
155	Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence. Urology, 2017, 108, 129-134.	0.5	17
156	Does PSADT After Radical Prostatectomy Correlate With Overall Survival?—A Report From the SEARCH Database Group. Urology, 2011, 77, 149-153.	0.5	16
157	Evaluation of a genomic classifier in radical prostatectomy patients with lymph node metastasis. Research and Reports in Urology, 2016, Volume 8, 77-84.	0.6	16
158	Predictors of operative time during radical retropubic prostatectomy and robotâ€assisted laparoscopic prostatectomy. International Journal of Urology, 2017, 24, 618-623.	0.5	16
159	Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 289.e11-289.e17.	0.8	16
160	Initial Experience with Aspirin Use During Robotic Radical Prostatectomy. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2012, 22, 225-229.	0.5	15
161	Feasibility of Transrectal Hybrid Natural Orifice Transluminal Endoscopic Surgery (NOTES) Nephrectomy in the Cadaveric Model. Urology, 2012, 80, 590-595.	0.5	15
162	Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 547-554.	1.1	15

#	Article	IF	CITATIONS
163	Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer. Journal of Urology, 2017, 198, 1309-1315.	0.2	15
164	Validation of the 2015 prostate cancer grade groups for predicting longâ€term oncologic outcomes in a shared equalâ€access health system. Cancer, 2017, 123, 4122-4129.	2.0	15
165	Threeâ€month posttreatment prostateâ€specific antigen level as a biomarker of treatment response in patients with intermediateâ€risk or highâ€risk prostate cancer treated with androgen deprivation therapy and radiotherapy. Cancer, 2018, 124, 2939-2947.	2.0	15
166	Obese patients with castrationâ€resistant prostate cancer may be at a lower risk of allâ€cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU International, 2018, 122, 76-82.	1.3	15
167	Predictors of skeletalâ€related events and mortality in men with metastatic, castrationâ€resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer, 2019, 125, 4003-4010.	2.0	15
168	Obesity, risk of biochemical recurrence, and prostateâ€specific antigen doubling time after radical prostatectomy: results from the SEARCH database. BJU International, 2019, 124, 69-75.	1.3	15
169	The Effect of Race/Ethnicity on the Accuracy of the 2001 Partin Tables for Predicting Pathologic Stage of Localized Prostate Cancer. Urology, 2008, 71, 151-155.	0.5	14
170	Comparison of Transrectal and Transvaginal Hybrid Natural Orifice Transluminal Endoscopic Surgery Partial Nephrectomy in the Porcine Model. Urology, 2013, 82, 84-89.	0.5	14
171	Weight Loss Following Radical Cystectomy forÂBladder Cancer: Characterization and EffectÂonÂSurvival. Clinical Genitourinary Cancer, 2017, 15, 86-92.	0.9	14
172	The effect of kidney morcellation on operative time, incision complications, and postoperative analgesia after laparoscopic nephrectomy. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2006, 32, 273-280.	0.7	14
173	Preclinical Evaluation of Robotic-Assisted Sentinel Lymph Node Fluorescence Imaging. Journal of Nuclear Medicine, 2014, 55, 1552-1556.	2.8	13
174	Impact of prior local therapy on overall survival in men with metastatic castrationâ€resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. International Journal of Urology, 2018, 25, 998-1004.	0.5	13
175	Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 633-635.	2.0	13
176	Establishment and Analysis of Three-Dimensional (3D) Organoids Derived from Patient Prostate Cancer Bone Metastasis Specimens and their Xenografts. Journal of Visualized Experiments, 2020, , .	0.2	13
177	Diabetes and Prostate Cancer Outcomes in Obese and Nonobese Men After Radical Prostatectomy. JNCI Cancer Spectrum, 2021, 5, pkab023.	1.4	13
178	Estimated blood loss as a predictor of PSA recurrence after radical prostatectomy: results from the SEARCH database. BJU International, 2010, 105, 347-351.	1.3	12
179	Does radical nephrectomy increase the risk of erectile dysfunction compared with partial nephrectomy? A cohort analysis. BJU International, 2013, 111, E98-102.	1.3	12
180	Is clinical stage T2c prostate cancer an intermediate†or high†isk disease?. Cancer, 2015, 121, 1414-1421.	2.0	12

#	Article	IF	CITATIONS
181	Prostateâ€specific antigen level, stage or Gleason score: Which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. International Journal of Urology, 2015, 22, 362-366.	0.5	12
182	Do all men with pathological Gleason score 8–10 prostate cancer have poor outcomes? Results from the <scp>SEARCH</scp> database. BJU International, 2016, 118, 250-257.	1.3	12
183	First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 239.e17-239.e25.	0.8	12
184	Update of staging and risk assessment for prostate cancer patients. Current Opinion in Urology, 2004, 14, 163-170.	0.9	11
185	What Do I Tell Patients About Saw Palmetto for Benign Prostatic Hyperplasia?. Urologic Clinics of North America, 2011, 38, 261-277.	0.8	11
186	Diabetes predicts metastasis after radical prostatectomy in obese men: results from the <scp>SEARCH</scp> database. BJU International, 2013, 111, E310-8.	1.3	11
187	Practice Patterns and Predictors of Followup Imaging after a Negative Bone Scan in Men with Castration Resistant Prostate Cancer: Results from the SEARCH Database. Journal of Urology, 2015, 193, 1232-1238.	0.2	11
188	Active Surveillance of Prostate Cancer in a Community Practice: How to Measure, Manage, and Improve?. Urology, 2016, 93, 60-67.	0.5	11
189	In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database. European Urology Focus, 2017, 3, 480-486.	1.6	11
190	Experience with 10Âyears of a robotic surgery program at an Academic Medical Center. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 1950-1960.	1.3	11
191	Adenocarcinoma of the prostate metastatic to the choroid of the eye. Prostate, 1995, 27, 336-339.	1.2	10
192	Drug-seeking behavior in urolithiasis in the noncontrast computed tomography era: 2 cases. Urology, 1999, 54, 744.	0.5	10
193	Watchful waiting versus active surveillance: Appropriate patient selection. Current Urology Reports, 2008, 9, 211-216.	1.0	10
194	Reâ€calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy. BJU International, 2010, 105, 1654-1659.	1.3	10
195	Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. International Journal of Urology, 2015, 22, 658-662.	0.5	10
196	Association between Radical Prostatectomy and Survival in Men with Clinically Node-positive Prostate Cancer. European Urology Oncology, 2019, 2, 584-588.	2.6	10
197	Impact of Obesity on the Utility of Preoperative Prostate-Specific Antigen Velocity to Predict for Relapse After Prostatectomy: A Report from the SEARCH Database. Urology, 2007, 69, 921-926.	0.5	9
198	Postoperative prostateâ€specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases. International Journal of Urology, 2010, 17, 914-922.	0.5	9

#	Article	IF	Citations
199	Laparo-Endoscopic Single-Site Surgery for Radical and Cytoreductive Nephrectomy, Renal Vein Thrombectomy, and Partial Nephrectomy: A Prospective Pilot Evaluation. Diagnostic and Therapeutic Endoscopy, 2010, 2010, 1-8.	1.5	9
200	A Family History of Lethal Prostate Cancer and Risk of Aggressive Prostate Cancer in Patients Undergoing Radical Prostatectomy. Scientific Reports, 2015, 5, 10544.	1.6	9
201	Radical prostatectomy and the effect of close surgical margins: results from the Shared Equal Access Regional Cancer Hospital ( <scp>SEARCH</scp> ) database. BJU International, 2018, 122, 592-598.	1.3	9
202	Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy. Journal of Urology, 2020, 204, 511-517.	0.2	9
203	Virtual reality suturing task as an objective test for robotic experience assessment. BMC Urology, 2015, 15, 63.	0.6	8
204	Validation of a bone scan positivity risk table in nonâ€metastatic castrationâ€resistant prostate cancer. BJU International, 2016, 118, 570-577.	1.3	8
205	Race does not predict the development of metastases in men with nonmetastatic castrationâ€resistant prostate cancer. Cancer, 2016, 122, 3848-3855.	2.0	8
206	Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH. Prostate, 2017, 77, 1592-1600.	1.2	8
207	Prospective Comparison of Computerized Tomography and Excretory Urography in the Initial Evaluation of Asymptomatic Microhematuria. Journal of Urology, 2002, , 2457-2460.	0.2	8
208	Impact of renal surgery for cortical neoplasms on lipid metabolism. BJU International, 2014, 114, 837-843.	1.3	7
209	Adverse pathology and undetectable ultrasensitive prostateâ€specific antigen after radical prostatectomy: is adjuvant radiation warranted?. BJU International, 2016, 117, 897-903.	1.3	7
210	Change in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma. BJU International, 2016, 118, 927-934.	1.3	7
211	Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group. Journal of Urology, 2018, 199, 713-718.	0.2	7
212	Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database. Clinical Genitourinary Cancer, 2019, 17, e140-e149.	0.9	7
213	Novel Dormancy Mechanism of Castration Resistance in Bone Metastatic Prostate Cancer Organoids. International Journal of Molecular Sciences, 2022, 23, 3203.	1.8	7
214	Is computed tomography a necessary part of a metastatic evaluation for castrationâ€resistant prostate cancer? Results from <scp>the Shared Equal Access Regional Cancer Hospital Database</scp> . Cancer, 2016, 122, 222-229.	2.0	6
215	Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer. Asian Journal of Urology, 2016, 3, 229-239.	0.5	6
216	Nerve-sparing Technique During Radical Prostatectomy and its Effect on Urinary Continence. European Urology, 2016, 69, 590-591.	0.9	6

#	Article	IF	Citations
217	Subcastrate Testosterone Nadir and Clinical Outcomes in Intermediate- or High-Risk Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 103, 1068-1076.	0.4	6
218	Obese men undergoing radical prostatectomy: Is robotic or retropubic better to limit positive surgical margins? Results from SEARCH. International Journal of Urology, 2020, 27, 851-857.	0.5	6
219	Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease. Prostate Cancer and Prostatic Diseases, 2020, 23, 689-695.	2.0	6
220	Association between Delay to Radical Prostatectomy and Clinically Meaningful Outcomes among Patients with Intermediate and High-Risk Localized Prostate Cancer. Journal of Urology, 2022, 207, 592-600.	0.2	6
221	Agent Orange and long-term outcomes after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 329.e1-329.e6.	0.8	5
222	Safety of concomitant therapy with radiumâ€223 and abiraterone or enzalutamide in a realâ€world population. Prostate, 2021, 81, 390-397.	1.2	5
223	African-American men with low-risk prostate cancer treated with radical prostatectomy in an equal-access health care system: implications for active surveillance. Prostate Cancer and Prostatic Diseases, 2020, 23, 581-588.	2.0	4
224	LIMITED VALUE OF BONE SCINTIGRAPHY AND COMPUTED TOMOGRAPHY IN ASSESSING BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 1999, , 176.	0.2	4
225	Robotic-Assisted Laparoscopic Prostatectomy for High-Risk Prostate Cancer: Technical Considerations and Review of the Literature. ISRN Urology, 2011, 2011, 1-7.	1.5	4
226	What is the Incidence of Kidney Stones after Chemotherapy in Patients with Lymphoproliferative or Myeloproliferative Disorders?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2014, 40, 772-780.	0.7	3
227	Characterization of a "lowâ€risk―cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database. International Journal of Urology, 2017, 24, 611-617.	0.5	3
228	First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH. Cancer Causes and Control, 2019, 30, 259-269.	0.8	3
229	Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy. Cancer, 2019, 125, 3025-3032.	2.0	3
230	Practice patterns and outcomes of equivocalÂbone scans for patients with castration-resistant prostate cancer: ResultsÂfrom SEARCH. Asian Journal of Urology, 2019, 6, 242-248.	0.5	3
231	Does race predict the development of metastases in men who receive androgenâ€deprivation therapy for a biochemical recurrence after radical prostatectomy?. Cancer, 2019, 125, 434-441.	2.0	3
232	Race does not predict skeletalâ€related events and allâ€cause mortality in men with castrationâ€resistant prostate cancer. Cancer, 2020, 126, 3274-3280.	2.0	3
233	Do Hispanic Men Have Worse Outcomes After Radical Prostatectomy? Results From SEARCH. Urology, 2021, 149, 181-186.	0.5	3
234	Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database. Journal of Urology, 2020, 203, 120-127.	0.2	3

#	Article	IF	CITATIONS
235	Prostate weight and prostate cancer outcomes after radical prostatectomy: Results from the SEARCH cohort study. Prostate, 2022, 82, 366-372.	1.2	3
236	KIDNEY GENE DATABASE: A CURATED AND INTEGRATED DATABASE OF GENES INVOLVED IN KIDNEY DISEASE. Journal of Urology, 2004, 172, 2344-2346.	0.2	2
237	Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. International Journal of Urology, 2016, 23, 241-246.	0.5	2
238	Focus on Transitional Disease: A Critical Interval to Delay Progression of Prostate Cancer. Oncology, 2021, 35, 166-168.	0.4	2
239	Impact of age on treatment response in men with prostate cancer treated with radiotherapy. BJUI Compass, 2022, 3, 243-250.	0.7	2
240	Racial Differences in Prognostic Value of Adult Height for Biochemical Progression Following Radical Prostatectomy. Clinical Cancer Research, 2005, 11, 7735-7742.	3.2	1
241	Laparoscopic Approaches to Renal Malignancies. Current Problems in Cancer, 2006, 30, 168-193.	1.0	1
242	Does Salvage Radiation Therapy Change the Biology of Recurrent Prostate Cancer Based on PSA Doubling Times? Results from the SEARCH Database. Urology, 2012, 79, 1105-1110.	0.5	1
243	Editorial Comment. Urology, 2014, 83, 1367-1368.	0.5	1
244	Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing?. Clinical Genitourinary Cancer, 2019, 17, e930-e938.	0.9	1
245	Monocyte counts and prostate cancer outcomes in white and black men: results from the SEARCHÂdatabase. Cancer Causes and Control, 2021, 32, 189-197.	0.8	1
246	The Impact of Comorbidity and Age on Timing of Androgen Deprivation Therapy in Men with Biochemical Recurrence after Radical Prostatectomy. Urology Practice, 2021, 8, 238-245.	0.2	1
247	Conservative Management of Ureteral Calculi., 2007,, 457-464.		1
248	RE: METASTATIC ADENOCARCINOMA OF THE PROSTATE TO THE CHOROID WITH LOSS OF VISUAL ACUITY AS A PRESENTING SYMPTOM. Journal of Urology, 1999, 162, 809-809.	0.2	0
249	Watchful waiting versus active surveillance: Appropriate patient selection. Current Prostate Reports, 2009, 7, 5-10.	0.1	О
250	Editorial Comment from <scp>D</scp> r <scp>L</scp> iss and <scp>D</scp> r <scp>K</scp> ane to Lymphocele after extraperitoneal robotâ€assisted radical prostatectomy: A propensity scoreâ€matching study. International Journal of Urology, 2013, 20, 1177-1177.	0.5	0
251	Risk versus benefit of lymph node dissection during prostatectomy. Nature Reviews Urology, 2013, 10, 262-263.	1.9	O
252	Reply. Urology, 2014, 84, 319-320.	0.5	0

#	Article	IF	CITATIONS
253	Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer—Results from the SEARCH database. Cancer Epidemiology, 2015, 39, 1066-1070.	0.8	O
254	Does salvage radiation therapy (SRT) change the biology of recurrent prostate cancer (PCa) based on PSA doubling timesÂ(PSADT)?ÂResults from the SEARCH database Journal of Clinical Oncology, 2012, 30, 203-203.	0.8	0
255	Robotic Pelvic Lymphadenectomy: Standard and Extended Techniques. , 2017, , 323-330.		O
256	Reply by Authors. Journal of Urology, 2020, 203, 127-127.	0.2	0
257	Robotic prostatectomy improves outcomes-after the potentially risky adoption phase. Oncology, 2012, 26, 626, 628, 630.	0.4	0
258	Radium-223 Utilization Patterns and Outcomes in Clinical Practice. Urology Practice, 0, , .	0.2	0